“Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s437. doi:10.25251/skin.8.supp.437.